Risk factors and predictors that influence SARS-Cov-2 IgG positivity

References

1. 1.↵
   1. Zhu N,
   2. Zhang D,
   3. Wang W,
   4. Li X,
   5. Yang B,
   6. Song J, et al.

   A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733.

   OpenUrlCrossRefPubMed
2. 2.↵
   World Health Organizaiton. WHO Coronavirus Disease. [Updated 2021. Accessed 2021 Feb 21]. Available from: https://covid19.who.int/
3. 3.↵
   1. Alahmari AA,
   2. Khan AA,
   3. Elganainy A,
   4. Almohammadi EL,
   5. Hakawi AM,
   6. Assiri AM, et al.

   Epidemiological and clinical features of COVID-19 patients in Saudi Arabia. J Infect Public Health 2021; 14: 437–443.

   OpenUrl
4. 4.↵
   Ministry of Health. COVID 19 Dashboard: Saudi Arabia. [Updated 2021. Accessed 2021 Feb 21]. Available from: https://covid19.moh.gov.sa/
5. 5.↵
   1. Wiersinga WJ,
   2. Rhodes A,
   3. Cheng AC,
   4. Peacock SJ,
   5. Prescott HC

   . Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 324: 782–793.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mizumoto K,
   2. Kagaya K,
   3. Zarebski A,
   4. Chowell G.

   Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan. Euro Surveill 2020; 25: 2000180.

   OpenUrlCrossRef
7. 7.↵
   1. Kimball A,
   2. Hatfield KM,
   3. Arons M,
   4. James A,
   5. Taylor J,
   6. Spicer K, et al.

   Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility — King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 377–381.

   OpenUrlCrossRefPubMed
8. 8.↵
   Public Health Considerations: Serologic Testing for COVID-19. [Updated 2020. Accessed 2021 February 22]. Available from: https://www.aphl.org/programs/preparedness/crisis-management/documents/serologic-Testing-for-COVID-19.pdf
9. 9.↵
   1. Vabret N,
   2. Britton GJ,
   3. Gruber C,
   4. Hegde S,
   5. Kim J,
   6. Kuksin M, et al.

   Immunology of COVID-19: current state of the science. Immunity 2020; 52: 910–941.

   OpenUrlCrossRefPubMed
10. 10.↵
    European Centre for Disease Prevention and Control. Immune responses and immunity to SARS-CoV-2. COVID19 latest Evid. (Updated 2020. Accessed June 2020]. Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses
11. 11.↵
    1. Wang Y,
    2. Zhang L,
    3. Sang L,
    4. Ye F,
    5. Ruan S,
    6. Zhong B, et al.

    Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest 2020; 130: 5235–5244.

    OpenUrlPubMed
12. 12.↵
    1. Huang AT,
    2. Garcia-Carreras B,
    3. Hitchings MDT,
    4. Yang B,
    5. Katzelnick LC,
    6. Rattigan SM, et al.

    A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun 2020; 11: 4704.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Poustchi H,
    2. Darvishian M,
    3. Mohammadi Z,
    4. Shayanrad A,
    5. Delavari A,
    6. Bahadorimonfared A, et al.

    SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis 2021; 21: 473–481.

    OpenUrl
14. 14.↵
    1. Jääskeläinen AJ,
    2. Kuivanen S,
    3. Kekäläinen E,
    4. Ahava MJ,
    5. Loginov R,
    6. Kallio-Kokko H, et al.

    Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol 2020; 129: 104512.

    OpenUrlCrossRef
15. 15.↵
    1. Ng DL,
    2. Goldgof GM,
    3. Shy BR,
    4. Levine AG,
    5. Balcerek J,
    6. Bapat SP, et al.

    SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun 2020; 11: 1–7.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Iyer AS,
    2. Jones FK,
    3. Nodoushani A,
    4. Kelly M,
    5. Becker M,
    6. Slater D, et al.

    Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020; 5: eabe0367.

    OpenUrlAbstract/FREE Full Text
17. 17.
    1. Isho B,
    2. Abe KT,
    3. Zuo M,
    4. Jamal AJ,
    5. Rathod B,
    6. Wang JH, et al.

    Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol 2020; 5: eabe5511.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Jiang XL,
    2. Wang GL,
    3. Zhao XN,
    4. Yan FH,
    5. Yao L,
    6. Kou ZQ, et al.

    Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. Nat Commun 2021; 12: 897.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Long QX,
    2. Tang XJ,
    3. Shi QL,
    4. Li Q,
    5. Deng HJ,
    6. Yuan J, et al.

    Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26: 1200–1204.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Alserehi HA,
    2. Alqunaibet AM,
    3. Al-Tawfiq JA,
    4. Alharbi NK,
    5. Alshukairi AN,
    6. Alanazi KH, et al.

    Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagn Microbiol Infect Dis 2021; 99: 115273.

    OpenUrl
21. 21.↵
    1. Mahallawi WH,
    2. Al-Zalabani AH.

    The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. Saudi J Biol Sci 2020; 28: 1697–1701.

    OpenUrl
22. 22.
    1. Alandijany TA,
    2. El-Kafrawy SA,
    3. Al-Ghamdi AA,
    4. Qashqari FS,
    5. Faizo AA,
    6. Tolah AM, et al.

    Lack of antibodies to SARS-CoV-2 among blood donors during COVID-19 lockdown: A study from Saudi Arabia. Healthcare (Basel) 2021; 9: 51.

    OpenUrl
23. 23.↵
    1. Banjar A,
    2. Al-Tawfiq JA,
    3. Alruwaily A,
    4. Alserehi H,
    5. Al-Qunaibet A,
    6. Alaswad R, et al.

    Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia. Int J Infect Dis 2021; 104: 452–457.

    OpenUrl
24. 24.↵
    1. Cells H.

    Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. Final rule. Fed Regist 2004; 69: 29785–29834.

    OpenUrlPubMed
25. 25.↵
    Saudi Central Board for Accreditation Of Healthcare Institutions. National Standards for Clinical Laboratories & blood banks. 1st ed. 2015; 5–7.
26. 26.↵
    1. Bryan A,
    2. Pepper G,
    3. Wener MH,
    4. Fink SL,
    5. Morishima C,
    6. Chaudhary A, et al.

    Performance characteristics of the Abbott architect sars-cov-2 igg assay and seroprevalence in Boise, Idaho. J Clin Microbiol 2020; 58: e00941–20.

    OpenUrlPubMed
27. 27.↵
    Abbott Laboratories. Abbott ARCHITECT IgG SARS-CoV-2 assay. [Update 2020. Assessed 2021 Febarury 22]. Available from: https://www.fda.gov/media/137383/download
28. 28.↵
    1. Garcia-Basteiro AL,
    2. Moncunill G,
    3. Tortajada M,
    4. Vidal M,
    5. Guinovart C,
    6. Jiménez A, et al.

    Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun 2020; 11: 3500.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Lahner E,
    2. Dilaghi E,
    3. Prestigiacomo C,
    4. Alessio G,
    5. Marcellini L,
    6. Simmaco M, et al.

    Prevalence of Sars-Cov-2 infection in health workers (HWs) and diagnostic test performance: the experience of a teaching hospital in central Italy. Int J Environ Res Public Health 2020; 17: 1–12.

    OpenUrlCrossRefPubMed
30. 30.
    1. Behrens GMN,
    2. Cossmann A,
    3. Stankov MV,
    4. Witte T,
    5. Ernst D,
    6. Happle C, et al.

    Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. Infection 2020; 48: 631–634.

    OpenUrlCrossRef
31. 31.
    1. Cento V,
    2. Colagrossi L,
    3. Nava A,
    4. Lamberti A,
    5. Senatore S,
    6. Travi G, et al.

    Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect 2020; 81: e90–e92.

    OpenUrlCrossRef
32. 32.↵
    1. Iversen K,
    2. Bundgaard H,
    3. Hasselbalch RB,
    4. Kristensen JH,
    5. Nielsen PB,
    6. Pries-Heje M, et al.

    Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis 2020; 20: 1401–1408.

    OpenUrlPubMed
33. 33.↵
    1. Amendola A,
    2. Tanzi E,
    3. Folgori L,
    4. Barcellini L,
    5. Bianchi S,
    6. Gori M, et al.

    Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. Infect Control Hosp Epidemiol 2020; 41: 1468–1469.

    OpenUrl
34. 34.
    1. Galanis P,
    2. Vraka I,
    3. Fragkou D,
    4. Bilali A,
    5. Kaitelidou D.

    Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect 2020; 108: 120–134.

    OpenUrl
35. 35.↵
    1. Piccoli L,
    2. Ferrari P,
    3. Piumatti G,
    4. Jovic S,
    5. Rodriguez BF,
    6. Mele F, et al.

    Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health - Europe 2020; 1: 100013.

    OpenUrl
36. 36.↵
    1. Alhetheel A,
    2. Albarrag A,
    3. Shakoor Z,
    4. Somily A,
    5. Barry M,
    6. Altalhi H, et al.

    Assessment of Th1/Th2 cytokines among patients with Middle East respiratory syndrome coronavirus infection. Int Immunol 2020; 32: 799–804.

    OpenUrl
37. 37.↵
    1. Bolk E,
    2. Matuschek C,
    3. Fischer J.

    Loss of anti–SARS-CoV-2 antibodies in mild Covid-19. N Engl J Med 2020; 383: 1694–1695.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Nag DS,
    2. Chaudhry R,
    3. Mishra M,
    4. Rai S,
    5. Gupta M.

    A prospective study on rapidly declining SARS‐CoV‐2 IgG antibodies within one to three months of testing IgG positive: Can it lead to potential reinfections? Cureus 2020; 12: e11845.

    OpenUrl
39. 39.↵
    1. Marklund E,
    2. Leach S,
    3. Axelsson H,
    4. Nyström K,
    5. Norder H,
    6. Bemark M, et al.

    Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One 2020;15: e0241104.

    OpenUrlCrossRefPubMed
40. 40.
    1. Ren L,
    2. Zhang L,
    3. Chang D,
    4. Wang J,
    5. Hu Y,
    6. Chen H, et al.

    The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol 2020; 3: 780.

    OpenUrl
41. 41.↵
    1. Chen X,
    2. Pan Z,
    3. Yue S,
    4. Yu F,
    5. Zhang J,
    6. Yang Y, et al.

    Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct Target Ther 2020; 5: 180.

    OpenUrl
42. 42.↵
    1. Deeks JJ,
    2. Dinnes J,
    3. Takwoingi Y,
    4. Davenport C,
    5. Spijker R,
    6. Taylor-Phillips S, et al.

    Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 2020; 6: CD013652.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Tang F,
    2. Quan Y,
    3. Xin Z-T,
    4. Wrammert J,
    5. Ma M-J,
    6. Lv H, et al.

    Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study. J Immunol 2011; 186: 7264–7268.

    OpenUrlAbstract/FREE Full Text
44. 44.↵
    1. Tong JY,
    2. Wong A,
    3. Zhu D,
    4. Fastenberg JH,
    5. Tham T.

    The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: A systematic review and meta-analysis. Otolaryngol Head Neck Surg 2020; 163: 3–11.

    OpenUrlCrossRefPubMed
45. 45.
    1. Wee LE,
    2. Chan YFZ,
    3. Teo NWY,
    4. Cherng BPZ,
    5. Thien SY,
    6. Wong HM, et al.

    The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19. Eur Arch Otorhinolaryngol 2020; 277: 2389–2390.

    OpenUrlPubMed
46. 46.
    1. Lechien JR,
    2. Chiesa-Estomba CM,
    3. De Siati DR,
    4. Horoi M,
    5. Le Bon SD,
    6. Rodriguez A, et al.

    Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277: 2251–2261.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Moein ST,
    2. Hashemian SM,
    3. Mansourafshar B,
    4. Khorram‐Tousi A,
    5. Tabarsi P,
    6. Doty RL.

    Smell dysfunction: a biomarker for COVID‐19. Int Forum Allergy Rhinol 2020; 10: 944–950.

    OpenUrl
48. 48.↵
    1. Murray CJL,
    2. Piot P.

    The potential future of the COVID-19 pandemic: Will SARS-CoV-2 become a recurrent seasonal infection? JAMA 2021; 325: 1249–1250.

    OpenUrlCrossRefPubMed